BU — Burcon NutraScience Income Statement
0.000.00%
Last trade - 00:00
- CA$33.49m
- CA$38.14m
- CA$0.36m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.04 | 0.031 | 0.259 | 0.171 | 0.364 |
Cost of Revenue | |||||
Gross Profit | -1.18 | -0.815 | -0.527 | -1.28 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Operating Interest Expense / Income | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4.59 | 3.75 | 4.85 | 7.57 | 15.9 |
Operating Profit | -4.55 | -3.72 | -4.6 | -7.4 | -15.5 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -4.78 | -4.63 | -0.617 | -10.3 | -25.4 |
Net Income After Taxes | -4.78 | -4.63 | -0.617 | -10.3 | -25.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.78 | -4.63 | -0.617 | -10.3 | -25.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.78 | -4.63 | -0.617 | -10.3 | -25.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.109 | -0.059 | -0.006 | -0.094 | -0.16 |